Medical News Today Article – Expert commentary by nPOD investigators. “The beauty of this approach is the virtual lack of any adverse effects, since it would use the patients’ own cells.” –Prof. Paolo Fiorina…
As an autoimmune disease, Type 1 diabetes has long been thought to result from a complete immune system killing of the insulin-producing beta cells within the pancreas. Now, University of Florida Health researchers have made a striking discovery: some of the pancreas’ ability to produce insulin may remain for decades…
UFDI and nPOD investigators found that the presence of β-cells as well as insulitis several years after T1D diagnosis in children and young adults suggest that the chronicity of islet autoimmunity extends well into the post-diagnosis period.
UFDI investigators and collaborators found that granulocyte colony stimulating factor monotherapy did not affect C-peptide production, HbA1c, or insulin dose.This study supports the continued exploration of G-CSF and other mobilizing agents in subjects with T1D, but only when combined with immunodepleting agents where synergistic mechanisms of action have previously demonstrated…
UFDI investigators and collaborators at Arizona State University found that the Epstein-Barr virus may have a role in type 1 diabetes development.
Two recent publications explored different methods of delivering a vaccine for type 1 diabetes, both of which prevented 40 percent of mice from developing the disease.
UFDI faculty and a University of Miami researcher found that “reduced pancreas weight allows for comparisons across a wide range of donor ages by eliminating confounding variables.”…
The publication found that myxoma virus binds human T lymphocytes but does not enter and infect T cells until after activation.
Benjamin Keselowsky, Ph.D. has received a new NIH R01 grant for “Biomaterial Delivery System for Type 1 Diabetes Vaccine”. Funded by the National Institute of Diabetes and Digestive and Kidney Diseases in collaboration with UF Diabetes Institute Director, Mark Atkinson, Ph.D., and Clive Wasserfall, this, $1.5M grant will fund the investigation of biodegradable microparticle/hydrogel formulations delivering immuno-modulatory factors to targeted immune cell types for the prevention and reversal of T1D.
UF and UF Health faculty, postdoctoral fellows, and graduate students submitted a record number of original research presentations for the American Diabetes Association’s 74th Scientific Sessions held June 13-17, 2014 at the Moscone Center in San Francisco, California. This year's submissions represent one of the largest showcases of research emanating from UF.
